Research Topics
| Alex C SpyropoulosSummaryAffiliation: Clinical Thrombosis Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparinAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM 87108, USA
Chest 122:108-14. 2002..Results demonstrated equivalent safety and efficacy for home care with enoxaparin with a reduction in cost. Our objective was to validate these findings in the routine practice setting of a US health maintenance organization...- Anticoagulation with anisindione in a patient with a warfarin-induced skin eruptionAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Health Systems, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
Pharmacotherapy 23:533-6. 2003..Health care providers managing patients who are receiving oral anticoagulant therapy should be aware of the maculopapular allergic reactions associated with warfarin and consider alternative treatment options such as anisindione... - Managing oral anticoagulation requires expert experience and clinical evidenceAlex C Spyropoulos
Lovelace Sandia Health Systems, Clinical Thrombosis Center, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
J Thromb Thrombolysis 21:91-4. 2006.... 
Improving prevention and treatment of venous thromboembolism: clinical trial resultsCharles Mahan
Department of Outcomes Research, New Mexico Heart Institute, University of New Mexico, Albuquerque, NM 87102, USA
J Med Econ 15:611-22. 2012..These improvement strategies focus on increasing the use of thromboprophylaxis, implementing existing guidelines, and improving awareness...- Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin?Alex C Spyropoulos
Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
Clin Cornerstone 7:39-48. 2005..The aim of this article is to summarize efficacy, safety, and pharmacoeconomic considerations when selecting LMWH versus UFH for thrombosis management in VTE and NSTE ACS... - A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulationAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
Pharmacotherapy 24:649-58. 2004..We sought to determine whether an alternate strategy of outpatient-based perioperative disease management with low-molecular-weight heparin (LMWH) as bridge therapy provides the potential for cost savings... - Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack ratesCharles E Mahan
New Mexico Heart Institute, University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87102, USA
Thromb Haemost 108:291-302. 2012..The cost models may be utilised to estimate other countries' costs or VTE-specific disease states... - Management of venous thromboembolism in the elderlyAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
Drugs Aging 23:651-71. 2006..New anticoagulants that may be of potential benefit in this patient population include fondaparinux sodium, but clinical experience of this drug in the elderly remains limited... - Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)Alex C Spyropoulos
Lovelace Medical Center, Albuquerque, New Mexico, USA
Am J Cardiol 102:883-9. 2008.... - Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patientsAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Sandia Health Systems, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
Chest 128:958-69. 2005..Despite the availability of effective thromboprophylactic therapies, VTE prophylaxis continues to be underutilized in hospitalized medical patients... - Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapyAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM 87108, USA
Chest 125:1642-50. 2004..v. UH, administered in a hospital setting, or LMWH, administered primarily in the outpatient setting using disease management guidelines... - Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosingCharles E Mahan
Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Lovelace Rehabilitation Hospital, Lovelace Health Systems, 601 Dr Martin Luther King Jr Ave NE, Albuquerque, NM, 87102, USA
Intern Emerg Med 5:299-306. 2010..Newly published risk-assessment models may be beneficial in determining which patients would best benefit from BID UFH or TID UFH... - Deep-vein thrombosis: a United States cost model for a preventable and costly adverse eventCharles E Mahan
University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
Thromb Haemost 106:405-15. 2011..8 to $52 billion, $6.8 to $36 billion, and $3.4 to $27 billion, respectively... - Bridging of oral anticoagulation therapy for invasive proceduresAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Sandia Health Systems, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
Curr Hematol Rep 4:405-13. 2005..This paper reviews these clinical data on bridging therapy and provides an evidence-based perioperative management strategy for the at-risk patient on chronic OAC... - Prevention of venous thromboembolism in the cancer surgery patientAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
Cleve Clin J Med 75:S17-26. 2008..The risk-benefit profile of low-dose anticoagulant prophylaxis appears to be favorable even in many cancer patients undergoing neurosurgery, for whom pharmacologic VTE prophylaxis has been controversial because of bleeding risks... - Update in the treatment of venous thromboembolismDavid A Garcia
Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
Semin Respir Crit Care Med 29:40-6. 2008..In addition to presenting evidence relevant to the optimal duration of warfarin therapy, we highlight circumstances under which extended therapy with a parenteral agent such as a low molecular weight heparin might be preferable... - Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapyAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
Curr Med Res Opin 22:1109-22. 2006..This, however, creates a clinical dilemma, since discontinuing VKAs may place the patient at risk of thromboembolism... - Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizationsAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Medical Center, 5400 Gibson Blvd, SE, Albuquerque, NM 87108, USA
J Manag Care Pharm 13:475-86. 2007..Venous thromboembolism (VTE) is a common medical condition manifested as deep vein thrombosis (DVT) or pulmonary embolism (PE). Few data exist on the total economic burden of DVT and PE... - Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxisCharles E Mahan
University of New Mexico Health Sciences Center, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA
Clin Appl Thromb Hemost 18:45-58. 2012..0006). In conclusion, a pharmacy-led multifaceted intervention can significantly increase the rates of appropriate prophylaxis and significantly reduce the incidence of preventable VTE in hospitalized patients... - Brave new world: the current and future use of novel anticoagulantsAlex C Spyropoulos
Clinical Thrombosis Center, ABQ Health Partners, University of New Mexico Health Center College of Pharmacy, Albuquerque, NM 87102, USA
Thromb Res 123:S29-35. 2008.... - Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database studyAlex C Spyropoulos
University of New Mexico Health Sciences Center, Albuquerque, NM, USA
J Thromb Thrombolysis 28:458-64. 2009..2-11.4), and orthopedic versus abdominal surgery (OR 1.4; 95% CI: 1.4-1.6). Patients undergoing orthopedic or abdominal surgery remain at-risk for VTE. Implementation of national performance measures may help reduce the burden of VTE... - Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndromeDavid B Talmadge
University of New Mexico School of Medicine, Albuquerque, USA
Pharmacotherapy 23:674-7. 2003..No further complications occurred with long-term therapy. Although a rare complication of therapy, clinicians should monitor for the development of purple toes syndrome in patients taking warfarin... - Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparinAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, New Mexico 87108, USA
Clin Appl Thromb Hemost 14:63-74. 2008.... - Prevention of venous thromboembolism: clinical and economic implications. IntroductionAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
Am J Health Syst Pharm 63:S3-4. 2006 - Investigational treatments of venous thromboembolismAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Medical Center, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
Expert Opin Investig Drugs 16:431-40. 2007.... - The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic diseaseAlex C Spyropoulos
Clinical Thrombosis Center, Lovelace Health Systems, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
J Thromb Thrombolysis 15:227-32. 2003.... - Prevention of venous thromboembolism in the orthopedic surgery patientSteven B Deitelzweig
Department of Hospital Medicine, Ochsner Health System, New Orleans, LA 70121, USA
Cleve Clin J Med 75:S27-36. 2008..Extended-duration prophylaxis (for 4 to 5 weeks) is now recommended for patients undergoing hip arthroplasty or hip fracture repair. Patients undergoing knee arthroscopy do not require routine pharmacologic VTE prophylaxis... - Prevention of venous thromboembolism in the hospitalized medical patientAmir K Jaffer
Department of Medicine, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Cleve Clin J Med 75:S7-16. 2008.... - Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarinThomas M Hyers
Department of Internal Medicine, St Louis University School of Medicine, St Louis, MO, USA
J Thromb Thrombolysis 24:225-32. 2007..Home therapy in the usual practice setting should achieve substantial overall cost savings in the treatment of DVT... - Perioperative bridging therapy for the at-risk patient on chronic anticoagulationAlex C Spyropoulos
Dis Mon 51:183-93. 2005 - Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulationAlex C Spyropoulos
Clinical Thrombosis Center Lovelace Medical Center Albuquerque, New Mexico 87108, USA
Curr Opin Pulm Med 11:373-9. 2005.... - Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalizationMichael F Bullano
HealthCore, Inc, 800 Delaware Ave, Wilmington, DE 19801, USA
J Manag Care Pharm 11:663-73. 2005.... - Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patientsAlexander T Cohen
Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
Thromb Haemost 94:750-9. 2005..These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient... - Management patterns and outcomes of patients with venous thromboembolism in the usual community practice settingVincent J Willey
HealthCore, Inc, Wilmington, DE 19081, USA
Clin Ther 26:1149-59. 2004.... - Prevention of venous thromboembolismMario Pini
Medicina Interna II, Ospedale di Fidenza, Fidenza, Parma, Italy
Semin Thromb Hemost 32:755-66. 2006.... - Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous ThromboembolismVictor F Tapson
Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
Chest 132:936-45. 2007..Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)... 
Management of venous thromboembolism: why not treat it at home?Alex C Spyropoulos
Can Fam Physician 51:181-2, 184-5. 2005- Oral anticoagulation: preparing for changeEdith A Nutescu
University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
J Am Med Dir Assoc 5:2-11. 2004..Further, the results of clinical trials suggest that ximelagatran may be as effective as warfarin in preventing stroke and VTE... - The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)James D Douketis
McMaster University, Hamilton, Ontario, Canada
Chest 133:299S-339S. 2008.... - Primary prevention of venous thromboembolism in long-term care: identifying and managing the riskSylvia Haas
Institut für Experimentelle Onkologie und Therapieforschung, Universitat Munchen, Ismaninger Strasse 22, Munich, Germany
Clin Appl Thromb Hemost 14:149-58. 2008..This review addresses the role of risk assessment in the decision of when to provide prophylaxis to an individual in long-term care and highlights key management issues for those prescribed prophylaxis...